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Angiotensin action on vascular 
endothelium causes hypotension
Binding of angiotensin II (Ang II) and activation of its receptor 
(AT1R) on vascular smooth muscle cells induces potent 
vasoconstriction, acutely raising blood pressure by increasing 
vascular resistance. Multiple hemodynamic, hormonal, 
and neuronal control mechanisms in vivo moderate the 
vasoconstrictor tone of Ang II, and, among them, endothelium-
derived vasorelaxation is critical. Intriguingly, functional AT1Rs 
are present on endothelial cells, but their physiological role 
is unknown. Cell culture studies indicated that endothelial 
cell–AT1R stimulation produces vasodilator substances, but 
studies in isolated blood vessels were inconclusive. Th e low 
density of AT1R in endothelial cells and the relative dominance 
of AT1R in vascular smooth muscle cells render the study 
of functional attributes of AT1R in endothelium technically 
challenging. Ramchandran et al. overcame this limitation by 
generating transgenic mice in which the endothelium was the 
primary target of direct Ang II (endogenous or exogenous) 
stimulation. Th ey used the Tie1 promoter to drive endothelial-
specifi c expression of the constitutively active mutant of the rat 
AT1R transgene. Th ey used the single mutant N111G, which 
spontaneously activates intracellular calcium mobilization. 
Also, it can be fully activated by an Ang II analogue, which 
does not activate the native AT1R and is fully inhibited by the 
AT1R inverse agonist L-158809. Strikingly, the Tie1-AT1R 
transgenic mice displayed hypotension, bradycardia, attenuated 
pressor response to infused Ang II, increased blood and tissue 
nitric oxide, and elevated endothelial nitric oxide synthase and 
cyclic guanosine monophosphate. Th e resulting symptoms in 
the transgenic mice could be rescued with the AT1R blocker 
L-158809. Th ese fi ndings strongly suggest a vasodilatory role 
for the AT1R in endothelial cells under normal conditions. 
Moreover, the results imply that the Ang II action via the 
AT1R in endothelial cells is antagonistic to vasoconstriction in 
general, and it may even moderate the magnitude of functional 
response to Ang II in vascular smooth muscle. Th us, in vivo, 
this control mechanism of Ang II action could be involved 
in the altered hemodynamic regulation observed during 
endothelial dysfunction of hypertensive and cardiovascular 
diseases. (Proc Natl Acad Sci USA 2006; 103: 19087–19092)
Juan Oliver
Diffuse mesangial sclerosis and 
nephrotic syndrome caused by 
mutation in phospholipase Cε
Diff use mesangial sclerosis is a severe type of 
glomerulosclerosis seen in children that results in end-
stage renal failure within 5 years. Mutations in the Wilms 
tumor gene (WT1) and in one of the laminin genes are 
known to cause it. Most of the other genetic causes of 
glomerulosclerosis cause focal segmental glomerulosclerosis. 
In a recent paper, Hinkes et al. studied seven families with 
diff use mesangial sclerosis and identifi ed by positional 
cloning the gene responsible for the disease. It turned out to 
be phospholipase Cε1 (PLCε1), an enzyme that hydrolyzes 
inositol phospholipids, generating several important signal 
transduction intermediates such as inositol trisphosphate and 
diacylglycerol. Interestingly, two of the patients responded to 
steroids, but several progressed to end-stage renal disease.
Studies by these authors showed that this enzyme is 
expressed in podocytes as early as the capillary loop stage 
of glomerular development. Histology of patients with the 
mutations suggests that glomerular development is arrested 
at this stage. Knock-down of the PLCε1 orthologue also led to 
heavy proteinuria in the pronephric kidney in the zebrafi sh. 
However, surprisingly, PLCε1 has recently been deleted in 
mice, and Hinkes et al. found that these mice did not have 
proteinuria. Is this another example showing that mice and 
children are diff erent? Or is there more to this story than meets 
the eye? Future studies should prove interesting. (Nat Genet 
2006; 38: 1397–1405)
Qais Al-Awqati
 Localization of transgenic AT1R protein in the endothelium.
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 PLCε1 localizes to glomerular podocytes in the adult rat.
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Klotho converts the canonical FGF 
receptor into a specific receptor for 
FGF23
Fibroblast growth factor 23 (FGF23) has an FGF-like domain in 
its amino-terminal portion and has been classifi ed as the newest 
member of the FGF family. Circulating FGF23 comes mainly 
from cells derived from the osteoblast lineage and helps to 
maintain homeostasis in phosphate and vitamin D metabolism 
by regulating the sodium phosphate cotransporter and the key 
vitamin D-metabolizing enzymes CYP27B1 and CYP24A1 in 
the kidney. Th at is, FGF23 acts as a hormone that derives from 
bone and regulates kidney functions. While this action suggests 
that the kidney may have a specifi c receptor for FGF23, the 
molecular mechanism responsible for the renal action of FGF23 
remains unclear despite extensive work with renal cell lines.
To address the molecular events accounting for the renal 
specifi city of FGF23 action, Urakawa et al. analyzed the early 
response to FGF23 in vivo. Using a complementary DNA 
array, they discovered that intravenous injection of mice with 
FGF23 protein signifi cantly upregulated the expression of the 
gene early growth-responsive 1 (Egr-1) and phosphorylated 
extracellular signal-regulated kinase (ERK) in the kidney. 
Although most cells in the body are known to be capable of 
ERK phosphorylation and Egr-1 induction, these responses 
were not observed aft er FGF23 treatment in liver, heart, lung, 
spleen, stomach, small intestine, thymus, adrenal gland, brain, 
or skeletal muscles.
Th us, FGF23 treatment activated ERK and induced Egr-1 
expression in the kidney, probably through an unknown 
FGF23 receptor system that is specifi cally present in the 
kidney but not in cultured renal cells in vitro. To identify the 
molecule in murine renal homogenates that directly binds 
to FGF23, the authors analyzed several proteins adsorbed 
by FGF23-Sepharose. Matrix-assisted laser desorption/
ionization–time-of-fl ight mass spectrometry analysis revealed 
that the major protein was Klotho. Klotho is a membrane 
protein with a large extracellular domain and very short 
cytoplasmic region, which is predominantly expressed in the 
kidney but not in renal cells in vitro. While investigating the 
functional relationships between Klotho and FGF23, Urakawa 
et al. found that forced expression of Klotho allowed high-
affi  nity binding of FGF23 to renal cells and restored their 
ability to respond to FGF23. Moreover, FGF23 incompetence 
was induced by injection of wild-type mice with an anti-
Klotho monoclonal antibody, showing that Klotho is essential 
for endogenous FGF23 function. Because Klotho alone 
seemed to be incapable of intracellular signalling, the authors 
searched for other components of the FGF23 receptor and 
found that the fi broblast growth factor receptor FGFR1(IIIc) 
was converted by Klotho into the FGF23 receptor. Th us, the 
concerted action of Klotho and FGFR1(IIIc) reconstitutes 
the FGF23 receptor. Th ese fi ndings explain the phenotypic 
similarities between Klotho-defi cient and FGF23-null 
mice and provide important insights into the diversity and 
specifi city of interactions between fi broblast growth factors 
and their receptors. (Nature 2006; 444: 770–774)
Juan Oliver
Cardiotoxicity prevention by 
angiotensin-converting enzyme 
inhibition
Angiotensin-converting enzyme inhibitors (ACEIs) have been 
shown to slow the progression of many diseases, including 
progressive renal failure. Although their basic mechanism of 
action is fairly well understood, the reasons for their therapeutic 
benefi ts are not clear. In the heart, ACEIs slow progression of 
left  ventricular dysfunction in several diff erent clinical settings, 
including anthracycline-induced cardiomyopathy.
It was previously shown that the increase in troponin I 
soon aft er high-dose chemotherapy strongly predicts left  
ventricular dysfunction and poor cardiac outcome, particularly 
in patients showing a persistent troponin I increase. Work 
done in experimental models suggests that the cardiac renin–
angiotensin system plays an important role in the development 
of anthracycline-induced cardiomyopathy, and that treatment 
with ACEIs protects against chemotherapy-induced 
cardiotoxicity. Th ese results suggest that a prophylactic strategy 
based on the use of ACEIs in selected high-risk patients could 
prevent cardiotoxicity. Hence, Cardinale et al. performed a 
prospective, randomized, clinical study to evaluate the eff ect 
of enalapril treatment on the prevention of cardiotoxicity in 
cancer patients undergoing high-dose chemotherapy that is 
followed by an increase in troponin I.
Th e 473 cancer patients who showed a troponin I increase 
soon aft er chemotherapy were randomized to receive (n = 56) or 
not to receive (n = 58) enalapril. Treatment was started 1 month 
aft er chemotherapy and continued for 1 year. Cardiological 
evaluation was performed at baseline and at 1, 3, 6, and 
12 months aft erward. Th e primary end point was an absolute 
decrease of more than 10% in left  ventricular ejection fraction, 
with a decline below the normal limit value. A signifi cant 
reduction in left  ventricular ejection fraction and an increase in 
end-diastolic and end-systolic volumes were observed only in 
untreated patients. According to the Kaplan-Meier analysis, the 
incidence of the primary end point was signifi cantly higher in 
control subjects than in the ACEI group (43% versus 0%).
Hence, in high-risk patients (defi ned by increased troponin 
I) treated with chemotherapy, early treatment with enalapril 
prevented development of late cardiotoxicity. Because the 
pathogenesis of chemotherapy-induced cardiotoxicity is 
not well understood, the reason(s) for the benefi cial eff ect 
of enalapril remains unknown. However, these results 
are impressive and raise the question of whether ACEI 
therapy during administration of nephrotoxic drugs may be 
considered. (Circulation 2006; 114: 2474–2481)
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